{"preliminary_commentary":{"by_channel":{"x_thread":40,"podcast":27,"youtube":19},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03515837\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"TKI-resistant EGFR-mutant metastatic nonsquamous non-small cell lung cancer","name":"KEYNOTE-789","nct_id":"NCT03515837","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-789-nct03515837. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo) (either carboplatin Area Under the Curve \\[AUC\\] 5 via IV infusion Q3W for 4 cycles \\[Cycles 1-4\\] or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles \\[Cycles 1-4\\]).","label":"Pembro+Pemetrexed+Chemo","type":"EXPERIMENTAL"},{"description":"Participants receive normal saline solution via IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo)(either carboplatin AUC 5 via IV infusion Q3W for 4 cycles \\[Cycles 1-4\\] or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles \\[Cycles 1-4\\]).","label":"Placebo+Pemetrexed+Chemo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-10-02","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":492,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"pembrolizumab","otherNames":["MK-3475"],"type":"BIOLOGICAL"},{"name":"pemetrexed","otherNames":[],"type":"DRUG"},{"name":"carboplatin","otherNames":[],"type":"DRUG"},{"name":"cisplatin","otherNames":[],"type":"DRUG"},{"name":"saline solution","otherNames":["Normal saline solution"],"type":"DRUG"}],"last_update":"2024-11-22","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-01-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to ~40 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to ~51 months"}],"references":[{"citation":"Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, Inoue T, Rodriguez-Cid J, Zhang L, Yang CT, de la Mora Jimenez E, Zhou J, Perol M, Lee KH, Vicente D, Ichihara E, Riely GJ, Luo Y, Chirovsky D, Pietanza MC, Bhagwati N, Lu S. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. J Clin Oncol. 2024 Dec;42(34):4029-4039. doi: 10.1200/JCO.23.02747. Epub 2024 Aug 22.","pmid":"39173098","type":"RESULT"}],"start_date":{"date":"2018-06-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)","url":"https://clinicaltrials.gov/study/NCT03515837"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-789-nct03515837"}